Advertisement


Lalan S. Wilfong, MD, on Metastatic Solid Tumors: Limiting Low-Value Care

2018 ASCO Quality Care Symposium

Advertisement

Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.



Related Videos

Issues in Oncology

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Neeraj K. Arora, PhD, of the Patient Centered Outcomes Research Institute (PCORI), discusses his work at PCORI and the central role that patients play in improving care and outcomes.

To learn more, visit https://www.pcori.org/.

Issues in Oncology

Monika K. Krzyzanowska, MD, MPH, on Quality Improvement: Avoiding the Pitfalls

Monika K. Krzyzanowska, MD, MPH, of Princess Margaret Cancer Centre, summarized the Keynote Lecture, including the points that clinicians should carefully plan their quality improvement projects, understand the barriers to quality, and ensure their efforts are sustainable.

Issues in Oncology
Cost of Care

Douglas W. Blayney, MD, on Quality Care: Better, Safer, Cheaper

Douglas W. Blayney, MD, of Stanford University, and winner of the Joseph V. Simone Award for Excellence, summarizes his talk on the expense of cancer care and how we can reduce costs while maintaining safety and high value for people with cancer.

Issues in Oncology
Symptom Management
Pain Management

Angela M. Stover, PhD, on Patient-Reported Symptoms: Results From the STAR and PRO-TECT Trials

Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses study findings on ways to alert clinicians when patients signal symptoms such as pain or diarrhea that may be cause for concern (Abstract 158).

Issues in Oncology
Pain Management
Legislation

Fumiko Ladd Chino, MD, on Opioid-Associated Deaths in Patients With Cancer

Fumiko Ladd Chino, MD, of Duke University, discusses results from a population study she conducted of the opioid epidemic over the past 10 years and why these medications for cancer pain should continue to be excluded from restrictive-prescribing laws (Abstract 230).

Advertisement

Advertisement



Advertisement